Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,600 across all filing types
Latest filing 2026-06-10 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2025年度分红派息实施公告
Notice of Dividend Amount Classification · 93% confidence The document is a company announcement detailing the implementation of the 2025 profit distribution and cash dividend plan: dividend ratio, total amount, tax treatment, record date, ex-dividend date, payment method, and related attachments. This matches the definition of a Notice of Dividend Amount (DIV).
2026-06-10 Chinese
关于提前归还2023年度以简易程序向特定对象发行股票暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 85% confidence The document is a formal announcement (公告) by 特一药业集团股份有限公司 regarding the early repayment of funds temporarily used from its 2023 private share issuance to supplement working capital. It details a financing decision by the board and the return of the proceeds to the dedicated fundraising account. This is not an earnings release, management discussion, or board change, but rather an update on the use of fundraising proceeds and related capital management. Therefore, it falls under Capital/Financing Update (CAP).
2026-06-09 Chinese
关于公司为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 85% confidence The document is a corporate announcement detailing the progress of guarantees (“担保”) provided by the parent company for its wholly-owned subsidiaries’ bank credit facilities. It does not contain full financial statements, it is not a meeting presentation or voting result, nor is it an MD&A or earnings release. Instead, it reports on financing arrangements (credit lines and guarantees), which fits the Capital/Financing Update category.
2026-06-09 Chinese
关于2026年限制性股票激励计划首次授予登记完成的公告
Share Issue/Capital Change Classification · 90% confidence The document is a public announcement by 特一药业集团股份有限公司 about the completion of the first grant registration under its 2026 restricted stock incentive plan. It details the share grant date, number of shares, recipients, grant price, source of shares (repurchased treasury shares), vesting and lock‐up arrangements, performance targets, and related accounting and use of funds. This is not a full financial report, proxy, or AGM material, but a corporate disclosure of share issuance/allotment under a stock incentive plan – a change in the company's capital structure. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-06-07 Chinese
国浩律师（深圳）事务所关于特一药业集团股份有限公司2026年限制性股票激励计划调整及授予事项的法律意见书
Regulatory Filings Classification · 85% confidence The document is a standalone legal opinion letter provided by Grandall Law Firm regarding adjustments and grants under a 2026 restricted stock incentive plan. It does not contain financial statements, earnings metrics, or voting results, nor is it announcing a meeting or management change. It is a compliance/legal document submitted as part of regulatory filings (e.g., to a stock exchange or securities regulator). There is no specific category for lawyer opinions, so the correct fallback is Regulatory Filings (RNS).
2026-05-25 Chinese
关于向公司2026年限制性股票激励计划激励对象首次授予限制性股票的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement by 特一药业 regarding the first grant of restricted stock under its 2026 restricted stock incentive plan. It details the number of shares, price, recipients, and the plan’s terms. This is not a financial report (no full financial statements), earnings release, M&A, or management change; rather it’s an issuance of equity under a share‐based compensation plan. This falls under “Share Issue/Capital Change” (SHA).
2026-05-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.